Drugs / ADO-5030
last change Jul 2026 re-read 3 minutes ago

ADO-5030

Developed for
asthma
Investigated by
Adovate · University of Virginia

Trials 1

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT07281274 Jan → Jun 2026 overdue asthma Adovate Not yet recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as ADO-5030 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07281274 ↗
Route Oral “Single oral dose of ADO-5030.” NCT07281274 ↗